Top

Published in:

01-06-2014 | Research Article

SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis

Authors: Chunhua Liu, Xuefei Shi, Li Wang, Ying Wu, Feiyan Jin, Cuiqing Bai, Yong Song

Published in: Tumor Biology | Issue 6/2014

Abstract

The suppressor of zeste-12 protein (SUZ12), a core component of Polycomb repressive complex 2 (PRC2), is implicated in transcriptional silencing by generating di- and tri-methylation of lysine 27 on histone H3 (H3K27Me3). Although SUZ12 is known to be of great importance in several human cancer tumorigenesis, limited data are available on the expression profile and functional role of SUZ12 in non-small cell lung cancer (NSCLC). Here, we determined the expression level of SUZ12 in 40 paired clinical NSCLC tissues and adjacent normal tissues by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The results showed that SUZ12 was anomalously expressed in NSCLC tissues compared to adjacent noncancerous tissues (P < 0.05) and was highly correlated to tumor size, lymph node metastasis, and clinical stages (P < 0.05). Additionally, siRNA-mediated knockdown of SUZ12 could inhibit tumor cell growth, migration, and invasion, indicating that SUZ12 might function as an oncogene in NSCLC initiation and progression. Furthermore, we found that SUZ12 silencing significantly reduced the expression levels of transcription factor transcription factor E2F1 (E2F1) as well as potential metastasis promoters Rho-associated, coiled-coil-containing protein kinase 1 (ROCK1) and roundabout homolog 1 (ROBO1) through Western blot analysis. Altogether, we provide evidences suggesting that SUZ12 is an oncogene in NSCLC and can regulate NSCLC cells proliferation and metastasis partly via reducing E2F1, ROCK1, and ROBO1. Thus, SUZ12 may represent a new potential diagnostic marker for NSCLC and may be a novel therapeutic target for NSCLC intervention.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:10.3322/caac.20006.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.CrossRefPubMed

Wu YL, Zhou Q. Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets. 2012;16 Suppl 1:S45–50. doi:10.1517/14728222.2011.630663.CrossRefPubMed

Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics. 2013;6:53. doi:10.1186/1755-8794-6-53.PubMedCentralCrossRefPubMed

Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer—genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2013;157(2):125–36. doi:10.5507/bp.2013.034.

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi:10.1056/NEJMra0802714.CrossRefPubMed

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(24):3316–21. doi:10.1200/jco.2010.33.3757.CrossRef

Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441(7091):349–53. doi:10.1038/nature04733.CrossRefPubMed

Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (New York, NY). 2002;298(5595):1039–43. doi:10.1126/science.1076997.CrossRef

10.

Koyanagi M, Baguet A, Martens J, Margueron R, Jenuwein T, Bix M. EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem. 2005;280(36):31470–7. doi:10.1074/jbc.M504766200.CrossRefPubMed

11.

Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004;23(20):4061–71. doi:10.1038/sj.emboj.7600402.PubMedCentralCrossRefPubMed

12.

Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871–4. doi:10.1038/nature04431.CrossRefPubMed

13.

Herranz N, Pasini D, Diaz VM, Franci C, Gutierrez A, Dave N, et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. 2008;28(15):4772–81. doi:10.1128/mcb.00323-08.PubMedCentralCrossRefPubMed

14.

Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761–72. doi:10.1016/j.molcel.2010.08.013.PubMedCentralCrossRefPubMed

15.

Villa R, Pasini D, Gutierrez A, Morey L, Occhionorelli M, Vire E, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer cell. 2007;11(6):513–25. doi:10.1016/j.ccr.2007.04.009.CrossRefPubMed

16.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(2):268–73. doi:10.1200/jco.2005.01.5180.CrossRef

17.

Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 2007;67(5):547–56. doi:10.1002/pros.20550.CrossRefPubMed

18.

Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003;100(20):11606–11. doi:10.1073/pnas.1933744100.PubMedCentralCrossRefPubMed

19.

Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosom Cancer. 2006;45(7):639–45. doi:10.1002/gcc.20327.CrossRefPubMed

20.

Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9. doi:10.1038/nature01075.CrossRefPubMed

21.

Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012;10(11):1462–72. doi:10.1158/1541-7786.mcr-12-0335.PubMedCentralCrossRefPubMed

22.

Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, et al. Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol. 2010;177(2):930–42. doi:10.2353/ajpath.2010.090769.PubMedCentralCrossRefPubMed

23.

Hallstrom TC, Mori S, Nevins JR. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer cell. 2008;13(1):11–22. doi:10.1016/j.ccr.2007.11.031.PubMedCentralCrossRefPubMed

24.

Saito M, Helin K, Valentine MB, Griffith BB, Willman CL, Harlow E, et al. Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. Genomics. 1995;25(1):130–8.CrossRefPubMed

25.

Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999;81(4):535–8.CrossRefPubMed

26.

Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 2000;9(4):395–401.PubMed

27.

Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006;16(7):890–900. doi:10.1101/gr.5306606.PubMedCentralCrossRefPubMed

28.

Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, et al. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol. 2008;61(5):601–5. doi:10.1136/jcp.2007.050963.CrossRefPubMed

29.

Kwong RA, Nguyen TV, Bova RJ, Kench JG, Cole IE, Musgrove EA, et al. Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(10 Pt 1):3705–11.

30.

Lee J, Park CK, Park JO, Lim T, Park YS, Lim HY, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(1):82–8. doi:10.1158/1078-0432.ccr-07-0612.CrossRef

31.

Moller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, et al. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 2000;14(5):898–904.CrossRefPubMed

32.

Rabbani F, Richon VM, Orlow I, Lu ML, Drobnjak M, Dudas M, et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst. 1999;91(10):874–81.CrossRefPubMed

33.

Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol. 2002;198(2):157–62. doi:10.1002/path.1185.CrossRefPubMed

34.

Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(23):6938–46. doi:10.1158/1078-0432.ccr-07-1539.CrossRef

35.

Gilkes DM, Xiang L, Lee SJ, Chaturvedi P, Hubbi ME, Wirtz D, et al. Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. Proc Natl Acad Sci U S A. 2014;111(3):E384–93. doi:10.1073/pnas.1321510111.PubMedCentralCrossRefPubMed

36.

Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, et al. MicroRNA 135a Suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PloS One. 2014;9(1):e85205. doi:10.1371/journal.pone.0085205.PubMedCentralCrossRefPubMed

37.

Wang J, Liu XH, Yang ZJ, Xie B, Zhong YS. The effect of ROCK-1 activity change on the adhesive and invasive ability of Y79 retinoblastoma cells. BMC Cancer. 2014;14(1):89. doi:10.1186/1471-2407-14-89.PubMedCentralCrossRefPubMed

38.

Zhang C, Zhang S, Zhang Z, He J, Xu Y, Liu S. ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc. Oncogene. 2013. doi:10.1038/onc.2013.505.

39.

Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67(2):171–7. doi:10.1007/s00018-009-0189-x.CrossRefPubMed

40.

Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG. The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol. 2008;33(3):585–93.PubMed

41.

Lin SL, Chang D, Ying SY. Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis. 2007;28(2):310–20. doi:10.1093/carcin/bgl134.CrossRefPubMed

42.

Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res. 2009;69(22):8742–51. doi:10.1158/0008-5472.can-09-1541.CrossRefPubMed

43.

Lochhead PA, Wickman G, Mezna M, Olson MF. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010;29(17):2591–8. doi:10.1038/onc.2010.3.CrossRefPubMed

44.

Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1–2):65–76. doi:10.1007/s10555-008-9170-7.CrossRefPubMed

45.

Guan H, Zu G, Xie Y, Tang H, Johnson M, Xu X, et al. Neuronal repellent Slit2 inhibits dendritic cell migration and the development of immune responses. J Immunol (Baltimore, Md : 1950). 2003;171(12):6519–26.CrossRef

46.

Bhat KM, Gaziova I, Krishnan S. Regulation of axon guidance by slit and netrin signaling in the Drosophila ventral nerve cord. Genetics. 2007;176(4):2235–46. doi:10.1534/genetics.107.075085.PubMedCentralCrossRefPubMed

47.

Dickson BJ, Gilestro GF. Regulation of commissural axon pathfinding by slit and its Robo receptors. Annu Rev Cell Dev Biol. 2006;22:651–75. doi:10.1146/annurev.cellbio.21.090704.151234.CrossRefPubMed

48.

Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, Goodman CS, et al. Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell. 1998;92(2):205–15.CrossRefPubMed

49.

Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, Roy A, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122(1):71–81. doi:10.1007/s00439-007-0375-6.CrossRefPubMed

50.

Narayan G, Goparaju C, Arias-Pulido H, Kaufmann AM, Schneider A, Durst M, et al. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer. 2006;5:16. doi:10.1186/1476-4598-5-16.PubMedCentralCrossRefPubMed

51.

Prasad A, Paruchuri V, Preet A, Latif F, Ganju RK. Slit-2 induces a tumor-suppressive effect by regulating beta-catenin in breast cancer cells. J Biol Chem. 2008;283(39):26624–33. doi:10.1074/jbc.M800679200.PubMedCentralCrossRefPubMed

Title: SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis
Authors: Chunhua Liu
Xuefei Shi
Li Wang
Ying Wu
Feiyan Jin
Cuiqing Bai
Yong Song
Publication date: 01-06-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1804-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2014

Polymorphisms of glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) in ovarian cancer risk

Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility

Esophageal cancer-selective expression of TRAIL mediated by MREs of miR-143 and miR-122

miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma

CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer

The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer